As the Global Insights Director for the Rare Disease Portfolio at Amgen, Janie Vitlina is at the forefront of transforming how insights drive strategic decision-making in the biopharmaceutical industry. With over 15 years of experience, Janie leads a dedicated team that focuses on harnessing healthcare...
As the Global Insights Director for the Rare Disease Portfolio at Amgen, Janie Vitlina is at the forefront of transforming how insights drive strategic decision-making in the biopharmaceutical industry. With over 15 years of experience, Janie leads a dedicated team that focuses on harnessing healthcare professional (HCP), patient, and payer insights to inform and enhance the company’s approach to rare diseases. Her role is pivotal in shaping the strategy for both in-market products and pipeline assets, ensuring that Amgen remains a leader in delivering innovative therapies that meet the unique needs of patients with rare conditions.
Janie’s expertise in customer-driven innovation and marketing analytics allows her to develop comprehensive insights that are not only actionable but also aligned with market demands. By leveraging advanced tools such as SPSS and Excel, she conducts rigorous survey designs and focus group analyses that uncover critical trends and preferences within the rare disease landscape. Her commitment to creative leadership fosters a culture of innovation within her team, encouraging out-of-the-box thinking that leads to breakthrough strategies and growth opportunities.
Key projects under Janie’s direction have included the development of targeted go-to-market strategies that integrate insights from diverse stakeholders, ensuring that Amgen’s offerings resonate with the needs of patients and healthcare providers alike. Her growth mindset and passion for continuous improvement drive her to seek new methodologies and approaches, positioning Amgen as a trailblazer in the rare disease sector. Through her leadership, Janie is not only building value through better insights but also making a meaningful impact on the lives of patients facing rare diseases.
